<DOC>
	<DOCNO>NCT00424086</DOCNO>
	<brief_summary>The objective study ass safety , tolerability immunogenicity Split Virus , Vero Cell derive , Seasonal Influenza Vaccine ( VCIV ) comparison Licensed Egg Derived , Split Virus , Seasonal Influenza Vaccine ( EIV ) healthy subject 18 year age old . Approximately 1000 subject randomly assign 3:1 ratio receive single injection VCIV EIV . Subjects monitor 180 day follow vaccination occurrence adverse reaction antibody response vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Study Inactivated Influenza Vaccine ( Split Virus , Vero Cell Derived )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject Are 18 49 year age ( inclusive ) day screen ( Stratum A ) Are 50 year age old day screening ( Stratum B ) Have understand study , agree provision , give write informed consent prior study entry Are clinically healthy ( physical condition physician would reservations administer influenza vaccine outside scope clinical study ) Are physically mentally capable participate study Agree keep daily record symptom If female capable bearing child , negative urine pregnancy test result within 24 hour vaccination Study Day 0 agree employ adequate birth control measure . For purpose study adequate birth control measure incorporate 2 type follow FDA approve birth control measure 60 day vaccination : Hormonal type birth control ( implant , birth control pill , patch method ) intrauterine device , AND An additional barrier type birth control measure ( i.e. , condom , diaphragm , cervical cap , etc . ) Subjects Have previously vaccinate influenza vaccine formulate 2006/2007 influenza season Have oral temperature &gt; =37.5°C time vaccination Day 0 ( see note ) Have Type I diabetes Have Body Mass Index &gt; 35 Have hypertension screening ( without medication ) grade great Stage 1 define systolic pressure &gt; 159 diastolic pressure &gt; 99 seat rest ( measurement may repeat twice subject absolutely exclude ) Have clinically significant abnormal clinical laboratory value screen Have clinically significant electrocardiographic abnormality screen Test positive Human Immunodeficiency Virus ( HIV ) , Hepatitis B Surface Antigen ( HbsAg ) Hepatitis C Virus ( HCV ) Have history cardiovascular disease require hospitalization Have history immunodeficiency autoimmune disease Have history arthritis ( joint swelling , tenderness , warmth erythema ) one occasion , relate trauma ( include run ) episode nontrauma related arthritis within previous 6 month Suffer active neoplastic disease history hematologic malignancy Suffer disease undergo form treatment expect influence immune response . Such treatment include , limited systemic high dose inhale ( &gt; 800 μg/day beclomethasone dipropionate equivalent ) corticosteroid , radiation treatment immunosuppressive cytotoxic drug Have history inflammatory degenerative neurological disease ( e.g . Guillain Barré , multiple sclerosis ) Have receive vaccination within 2 week prior vaccination study Have receive blood transfusion immunoglobulin within 30 day prior vaccination study Have donate blood plasma within 30 day prior vaccination study Have history vaccine relate contraindicate event ( e.g. , anaphylaxis , allergy egg , allergy component test comparator vaccine , know contraindication ) Have rash , dermatologic condition tattoo may interfere injection site reaction rating Have positive urine drug screen ( unless detect drug currently prescribe license health care provider continue administration drug would otherwise exclude subject participation ) Were administer investigational drug within 6 week prior study entry Are concurrently participate clinical study Inactivated Influenza Vaccine ( Split Virus , Vero Cell Derived ) include administration investigational product Are member team conducting study Are dependent relationship study investigator . Dependent relationship include close relative ( i.e. , child , partner/spouse , sibling , parent ) well employee investigator If female , pregnant lactating . NOTE : If inclusion/exclusion criterion meet , subject temperature &gt; =37.5°C Day 0 may include study repeat visit provide : 1 . They oral temperature &gt; =37.5°C repeat visit , 2 . The repeat visit 5 calendar day initial Day 0 visit , 3 . The repeat visit 21 calendar day screen procedure complete , 4 . Subjects still recruit study site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>